() -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse. Here are some reactions to Lilly joining the trillion dollar club: EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS "The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise.
() -AstraZeneca said on Friday it will invest $2 billion to expand its manufacturing footprint in Maryland as part of its previously announced $50 billion plan to expand manufacturing and research capabilities in the U. Global pharmaceutical companies have been ramping up investments in the United States to expand production capacity, following President Donald Trump's call for the industry to make more medicines domestically instead of importing active ingredients or finished products.
ZURICH () -Novartis will expand its operations in North Carolina and build a manufacturing hub there as part of a planned $23 billion of U. infrastructure investment over the next five years, the Swiss pharmaceuticals company said on Wednesday.
(Reuters) -Pfizer and supplier Tris Pharma reached a $41.5 million settlement with Texas to resolve a lawsuit claiming they defrauded the state's Medicaid program over alleged quality control lapses in a medicine to treat attention deficit hyperactivity disorder in children.
() -Moderna said on Wednesday it would now operate full end-to-end manufacturing for its mRNA medicines in the U., marking a major step in strengthening the company's domestic production network.
(Reuters) -Merck said on Monday it expects a commercial opportunity exceeding $5 billion from Cidara Therapeutics' experimental flu drug, and does not anticipate it to require a review by the U. CDC's vaccine advisory panel before launch.
COPENHAGEN (Reuters) -Novo Nordisk said on Monday it would lower the U. price of its injectable Wegovy obesity drug and pledged to go "all in" on its upcoming oral weight-loss pill, as the firm races to claw back lost ground in the lucrative market.
The Danish drugmaker said it's cutting the price of Wegovy and Ozempic from $499 to $349 per month for some customers who buy the drugs directly.
Comet 3I/ATLAS recently emerged from behind the glare of the sun to become visible to ground-based telescopes.
New versions of Cheetos and Doritos, without artificial flavors or dyes, will be sold in December.